Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz Pushing FDA To Make Biosimilar Interchangeability Decisions

Executive Summary

Absent guidance, the company says it is submitting proposals for trial designs it believes could demonstrate biosimilar interchangeability.

You may also be interested in...

Pediatric Study Waiver, Deferral Determinations Could Harm Approvals, Firms Tell FDA

Comments on draft guidance say agency’s belated decisions on requests for waivers or deferrals of pediatric studies could lead to “refuse to file” determinations; FDA has missed statutory deadline to promulgate regulations on pediatric study plans.

Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?

Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.

State Bills To Regulate Biosimilar Substitutions Make Headway

Seventeen states are considering legislation to set rules for biosimilar substitutions, including alerting the prescribing physician and keeping long-term records of the substitutions – steps that go beyond those in place for small-molecule generic drug substitutions.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts